Presentation is loading. Please wait.

Presentation is loading. Please wait.

Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart.

Published byJulian Maloney Modified over 10 years ago

Similar presentations

Presentation on theme: "Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart."— Presentation transcript:

1 Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart Baker (NIH/NCI) Marina Kondratovich (FDA/CDRH) Ping Shi (Abbott Diagnostics)

2 Session Description: This session is a sampling of some important statistical challenges that are present in the design and analysis of some diagnostic products. Speakers/Titles: "Classification rules for high-dimensional markers: searching for complementary marker pairs", Stuart Baker, NIH/NCI "Comparing the Diagnostic Accuracies of Two Tests in Studies with Verification Bias", Marina Kondratovich, FDA/CDRH "Computer Simulation in Medical Diagnostic Assay Calibration Evaluation", Ping Shi, PhD, Abbott Diagnostics

3 Comparing Diagnostic Accuracies of Two Tests in the Studies with Verification Bias Marina Kondratovich, Ph.D. Division of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration. No official support or endorsement by the Food and Drug Administration of this presentation is intended or should be inferred. September, 2005

4 Classification rules for high dimensional markers: searching for complementary marker pairs Stuart G. Baker, et al sb16i@nih.gov Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA

5 Computer Simulation in Medical Diagnostic Assay Calibration Evaluation Ping Shi Ph.D Abbott Laboratories Sept. 16, 2005

Download ppt "Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart."

Similar presentations

FDA QS reg/CLIA Comparison: Overview

FDA QS reg/CLIA Comparison: Overview
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
1 Comparing Diagnostic Accuracies of Two Tests in Studies with Verification Bias Marina Kondratovich, Ph.D. Division of Biostatistics, Center for Devices.

1 Comparing Diagnostic Accuracies of Two Tests in Studies with Verification Bias Marina Kondratovich, Ph.D. Division of Biostatistics, Center for Devices.
Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD 20850 * No official support.

Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD * No official support.
Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.

Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.
Interim Analysis in Clinical Trials: A Bayesian Approach in the Regulatory Setting Telba Z. Irony, Ph.D. and Gene Pennello, Ph.D. Division of Biostatistics.

Interim Analysis in Clinical Trials: A Bayesian Approach in the Regulatory Setting Telba Z. Irony, Ph.D. and Gene Pennello, Ph.D. Division of Biostatistics.
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,

The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
1 Propensity Scores Methodology for Receiver Operating Characteristic (ROC) Analysis. Marina Kondratovich, Ph.D. U.S. Food and Drug Administration, Center.

1 Propensity Scores Methodology for Receiver Operating Characteristic (ROC) Analysis. Marina Kondratovich, Ph.D. U.S. Food and Drug Administration, Center.
1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Parallel Session 1 The Role of the Statistician in Post- Marketing, Including Surveillance Organizers –Harry Bushar (FDA-CDRH) –Greg Campbell (FDA-CDRH)

Parallel Session 1 The Role of the Statistician in Post- Marketing, Including Surveillance Organizers –Harry Bushar (FDA-CDRH) –Greg Campbell (FDA-CDRH)
1 Other Issues for Statisticians in Medical Devices Gregory Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health,

1 Other Issues for Statisticians in Medical Devices Gregory Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health,
Discussion: Biostatistics in Public Policy

Discussion: Biostatistics in Public Policy
Wireless and Mobile Technologies for Healthcare: Ensuring Privacy, Security, and Availability Thomas Jepsen Chair, IEEE-USA Medical Technology Policy Committee.

Wireless and Mobile Technologies for Healthcare: Ensuring Privacy, Security, and Availability Thomas Jepsen Chair, IEEE-USA Medical Technology Policy Committee.
Development Cycle of Medical Devices: A Path of Opportunities for Information Professionals Donna Gay Pharma & Health Tech Div, SLA 2007 Spring Meeting.

Development Cycle of Medical Devices: A Path of Opportunities for Information Professionals Donna Gay Pharma & Health Tech Div, SLA 2007 Spring Meeting.
Regulatory Pathway for Platform Technologies

Regulatory Pathway for Platform Technologies
Determining the Regulatory Pathway to Market Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Clinical Trial Design, Biostatistics, Ethics, and Recruitment Clinical Trial Design  Anthony J. Murgo, MD.,MS; NCI/DCTD Biostatistics  Larry Rubinstein,

Clinical Trial Design, Biostatistics, Ethics, and Recruitment Clinical Trial Design  Anthony J. Murgo, MD.,MS; NCI/DCTD Biostatistics  Larry Rubinstein,
FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.

FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.
FOCUS ON NLM RESOURCES: CLINICALTRIALS.GOV. WHAT IS A CLINICAL STUDY?  Research study using human subjects.  Volunteers may have a certain disease or.

FOCUS ON NLM RESOURCES: CLINICALTRIALS.GOV. WHAT IS A CLINICAL STUDY?  Research study using human subjects.  Volunteers may have a certain disease or.
Becker Grand Rounds: Wally Pellerite June 30, 2011.

Becker Grand Rounds: Wally Pellerite June 30, 2011.

Similar presentations

Ads by Google